These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20019121)

  • 21. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease.
    Blaustein DA; Schwenk MH; Chattopadhyay J; Singh H; Daoui R; Gadh R; Avram MM
    Kidney Int Suppl; 2003 Nov; (87):S72-7. PubMed ID: 14531777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.
    Ibrahim HN; Foley RN; Zhang R; Gilbertson DT; Collins AJ
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):623-9. PubMed ID: 19211669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease.
    Agarwal R; Rizkala AR; Bastani B; Kaskas MO; Leehey DJ; Besarab A
    Am J Nephrol; 2006; 26(5):445-54. PubMed ID: 17035697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
    Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
    Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, therapeutic effectiveness, and cost of parenteral iron therapy.
    Asma S; Boga C; Ozdogu H
    Int J Hematol; 2009 Jul; 90(1):24-27. PubMed ID: 19495930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
    Diebold M; Kistler AD
    BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients.
    Mitsopoulos E; Lysitska A; Pateinakis P; Lamprou V; Intzevidou E; Minasidis I; Katsaounou C; Kougioumtzidou O; Anagnostou N; Lemonidis N; Papadopoulou D
    Int Urol Nephrol; 2020 Feb; 52(2):387-392. PubMed ID: 31894555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
    Seliger S; Fox KM; Gandra SR; Bradbury B; Hsu VD; Walker L; Chiou CF; Fink JC
    Clin J Am Soc Nephrol; 2010 May; 5(5):882-8. PubMed ID: 20299377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia].
    Cançado RD; Brasil SA; Noronha TG; Chiattone CS
    Rev Assoc Med Bras (1992); 2005; 51(6):323-8. PubMed ID: 16444338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients.
    Chuang CL; Liu RS; Wei YH; Huang TP; Tarng DC
    Nephrol Dial Transplant; 2003 Feb; 18(2):370-7. PubMed ID: 12543894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
    Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
    Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation.
    Singh AK; Coyne DW; Shapiro W; Rizkala AR;
    Kidney Int; 2007 Jun; 71(11):1163-71. PubMed ID: 17396118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
    Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Steenkamp R; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
    Am J Nephrol; 2018; 48(4):260-268. PubMed ID: 30304714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
    Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
    Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness*.
    Pieracci FM; Stovall RT; Jaouen B; Rodil M; Cappa A; Burlew CC; Holena DN; Maier R; Berry S; Jurkovich J; Moore EE
    Crit Care Med; 2014 Sep; 42(9):2048-57. PubMed ID: 24797376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.